William C Bertrand JR sold $7,813 of ADAPY
Chief Operating Officer at Adaptimmune Therapeutics PLC. 9,229 shares at an average of $0.85, traded Jan 11, 2024, filed Jan 12, 2024.
Score components
- +20RoleCOO
- 0Trade size$8k at market
- +20Share of holdings soldSold 91% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-003745, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 11, 2024 | SOpen-market sale American Depositary Shares representing Ordinary Shares | -4,009 | $0.84 | $3,354 | 6,104 | Jan 12, 2024 |
| Jan 12, 2024 | SOpen-market sale American Depositary Shares representing Ordinary Shares | -5,220 | $0.85 | $4,458 | 7,874 | Jan 12, 2024 |
Related signals
Other insiders at Adaptimmune Therapeutics PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Adaptimmune Therapeutics PLC | Gavin Wood Chief Financial Officer | $950 96,000 shares | -100% | |
| 40Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $2,091 207,000 shares | -17% | |
| 56Moderate | Adaptimmune Therapeutics PLC | Ali Behbahani director | $229k 19,500,000 shares | -100% | |
| 47Moderate | ADAPYsell Adaptimmune Therapeutics PLC | EcoR1 Capital, LLC owner | $6.9M 64,052,538 shares | -39% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Adrian Rawcliffe Chief Executive Officer | $18k 30,601 shares | -41% | |
| 45Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $3,243 5,584 shares | -43% | |
| 55Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $11k 19,542 shares | -193% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.